Diversion Control Division, US Department of Justice, Drug Enforcement Administration

Manufacturers Notice of Application - 2012

[Federal Register Volume 77, Number 152 (Tuesday, August 7, 2012)]
[Notices]
[Pages 47108-47109]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-19199]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application; Cerilliant Corporation

Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is notice that on July 6, 2012, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances:

Drug Schedule
Cathinone (1235)  I
Methcathinone (1237)  I
4-Methyl-N-methylcathinone (1248)  I
N-Ethylamphetamine (1475)  I
N,N-Dimethylamphetamine (1480)  I
Fenethylline (1503)  I
Gamma Hydroxybutyric Acid (2010)  I
JWH-018 (7118)  I
JWH-073 (7173)  I
JWH-200 (7200)  I
Alpha-ethyltryptamine (7249)  I
Ibogaine (7260)  I
CP-47497 (7297)  I
CP-47497 C8 Homologue (7298)  I
Lysergic acid diethylamide (7315)  I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) I
Marihuana (7360)  I
Tetrahydrocannabinols (7370)  I
Mescaline (7381)  I
3,4,5-Trimethoxyamphetamine (7390)  I
4-Bromo-2,5-dimethoxyamphetamine (7391)  I
4-Bromo-2,5-dimethoxyphenethylamine (7392)  I
4-Methyl-2,5-dimethoxyamphetamine (7395)  I
2,5-Dimethoxyamphetamine (7396)  I
3,4-Methylenedioxyamphetamine (7400)  I
3,4-Methylenedioxy-N-ethylamphetamine (7404)  I
3,4-Methylenedioxymethamphetamine (7405)  I
4-Methoxyamphetamine (7411)  I
5-Methoxy-N-N-dimethyltryptamine (7431)  I
Alpha-methyltryptamine (7432)  I
Diethyltryptamine (7434)  I
Dimethyltryptamine (7435)  I
Psilocybin (7437)  I
Psilocyn (7438)  I
5-Methoxy-N,N-diisopropyltryptamine (7439)  I
N-Benzylpiperazine (7493)  I
3,4-Methylenedioxypyrovalerone (7535)  I
3,4-Methylenedioxy-N-methylcathinone (7540)  I
Desomorphine (9055)  I
Etorphine (except HCl)(9056)  I
Heroin (9200)  I
Morphine-N-oxide (9307)  I
Normorphine (9313)  I
Pholcodine (9314)  I
Dextromoramide (9613)  I
Dipipanone (9622)  I
Racemoramide (9645)  I
Trimeperidine (9646)  I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661)  I
Tilidine (9750)  I
Amphetamine (1100)  II
Methamphetamine (1105)  II
Methylphenidate (1724)  II
Amobarbital (2125)  II
Pentobarbital (2270)  II
Secobarbital (2315)  II
Phencyclidine (7471)  II
Phenylacetone (8501)  II
Cocaine (9041)  II
Codeine (9050)  II
Dihydrocodeine (9120)  II
Oxycodone (9143)  II
Hydromorphone (9150)  II
Benzoylecgonine (9180)  II
Ethylmorphine (9190)  II
Meperidine (9230)  II
Methadone (9250)  II
Dextropropoxyphene, bulk (non-dosage forms)(9273)  II
Morphine (9300)  II
Oripavine (9330)  II
Thebaine (9333)  II
Levo-alphacetylmethadol (9648)  II
Oxymorphone (9652)  II
Poppy Straw Concentrate (9670)  II
Alfentanil (9737)  II
Sufentanil (9740)  II
Fentanyl (9801)  II

The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards.

In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration.

Comments and requests for hearing on applications to import narcotic raw material are not appropriate. 72 FR 3417(2007). Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR Sec. 1301.43 and in such form as prescribed by 21 CFR Sec. 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than September 6, 2012.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR Sec. 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR Sec. 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: July 30, 2012.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-19199 Filed 8-6-12; 8:45 am]

BILLING CODE 4410-09-P

 

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Printing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility